Get the Daily Brief
Latest Biotech News
Accelerated approval and setbacks in oncology
The FDA granted accelerated approval to Replimune’s oncolytic viral therapy Tudriqev (RP1) for advanced melanoma, ending a twice-rejected approval effort. The decision follows an advisory...
Regulatory wins in vaccines and infectious disease products
The FDA approved Moderna’s mRNA influenza vaccine mFlusiva (mRNA-1010), marking the first U.S. seasonal flu vaccine built on mRNA technology. The approval covers adults 50–64 and adults 65 and...
Biotech IPO momentum and large funding raises
Latigo Biotherapeutics priced its IPO to raise about $345.6 million for a non-opioid pain pipeline focused on the Nav1.8 channel pathway, part of a broader 2026 pattern of upsized biotech...
Molecular diagnostics and MRD: demand signals and platform expansion
Natera raised its outlook and emphasized faster prospective study readouts for its Signatera MRD test after reporting a 38% year-over-year jump in Q2 revenue. Executives said booked orders for its...
Gene editing and safety risks in China
China-based gene therapy has faced another reported safety concern: a boy receiving Huidagene’s gene editing therapy HG-302 for Duchenne muscular dystrophy died, according to the company’s...
First-in-class sleep and neurology approvals
Takeda’s oral orexin-2 receptor agonist Orzeyful (oveporexton) received FDA approval for narcolepsy type 1, with the company positioning the drug as the first therapy designed to address the...
Targeted cancer diagnostics and platform competition in spatial biology
Spatial Genomics and Caltech filed a lawsuit alleging 10x Genomics’ Xenium spatial biology platform infringes patents related to multiplex labeling using sequential hybridization barcoding. The...
Biopharma capital markets: UK VC surge
UK biotech venture capital hit a five-year high, with companies raising £2.05 billion in Q2 2026, driven in part by Isomorphic Labs’ £1.6 billion Series B. The BioIndustry Association said the...
FDA pathway and international expansion in life science tools
Illumina launched the MiSeq i100 Series-CN, a locally manufactured version of its MiSeq i100 sequencer produced for China’s domestic market. The company said the instrument is functionally...
Biotech innovation: protein degradation platform for molecular glue discovery
Dana-Farber researchers unveiled a platform for systematically discovering molecular glue degraders, aiming to broaden the therapeutic space beyond the small subset of E3 ligases currently used in...
Regulatory approvals: oncology (accelerated approval) rebound
Replimune won FDA accelerated approval for its oncolytic viral therapy Tudriqev (formerly RP1) for advanced melanoma, ending a two-rejection saga for the company. The FDA cleared Tudriqev in...
Regulatory decisions: rare disease and pediatric designations
IPS Heart Inc.’s ISX9-CPC received an FDA rare pediatric drug designation for cardiomyopathies associated with dystrophinopathies, positioning the program for incentives tied to pediatric...
FDA approvals: first-in-class orexin pathway sleep drug
Takeda’s oral orexin receptor 2 agonist oveporexton (Orzeyful) gained FDA approval as the first therapy designed to address underlying biology in narcolepsy type 1. The approval follows Phase 3...
Clinical data and diagnostics: ovarian function under ketamine and fertility protection
A new mouse study in Cell Death Discovery reports ketamine may protect ovarian function and improve egg quality in a stress-induced depression model. Researchers led by Liu, Jiang, Wang and...
Clinical evidence: fecal microbiome transplant in peanut allergy tolerance
Boston Children’s Hospital researchers reported Phase I results showing that oral encapsulated fecal microbiome transplantation (FMT) may raise peanut tolerance in adults with peanut allergy. In...
Diagnostics and workflows: AI embedded into oncology physician practice
OneOncology will embed OpenEvidence’s AI chatbot and search engine directly into clinic workflows, aiming to improve decision support for oncology practices and physician access to rapidly...
Regulatory review risk: FDA to convene adcomm for Grail’s failed cancer test
The FDA will hold an advisory committee meeting in September to review Grail’s Galleri multi-cancer early detection test after the product failed to meet the primary endpoint in a large,...
Biotech financing: blockbuster IPOs in 2026 and demand for early-stage growth
Four biotechs raised more than $1.2 billion in a strong IPO run, continuing a 2026 wave in which investors have shown renewed appetite for public offerings. The broader data point cited in the...
Translational biology: tau disrupts mitochondrial function via reverse electron transport
New preclinical work from Stanford Medicine and UCSF links tau pathology to mitochondrial reverse electron transport (RET), offering a mechanism that could be targeted beyond conventional tau...
Drug development and early-stage pipeline: ferroptosis linked to FLT3 inhibitors in AML
Researchers at Baylor College of Medicine and collaborating institutions identified a vulnerability in acute myeloid leukemia that connects FLT3-targeted therapy to ferroptosis, according to a...